Loading...

XAIR BEYOND AIR INC US FDA Inspections 8-K Filing

BYND

XR

BEYOND AIR INC

(XAIR)

2025 8-K

CEO Transition Announcement

Financial Results Update

Annual Meeting Results

Private Placement Offering

Acquisition Announcement

Management Change

Management Change

CFO Resignation

Financial Results Announcement

Funding Agreement

Capital Raise Agreement

FDA Grant Announcement

Quarterly Financial Results

Reverse Stock Split

Share Sale Agreement

Management Change

Equity Offering

Financial Results

Nasdaq Compliance Notice

Accounting Firm Change

Clinical Trial Approval

CE Mark Approval

Annual Meeting Results

Financial Results

Annual Meeting Notice

Securities Offering

Financial Results and Delis...

Loan Agreement Amendment an...

Equity Incentive Plan Approval

Termination of Sales Agreement

Financial Results and Consu...

Earnings Reports

Earnings Report

Financial Results Announcement

Equity Incentive Plan Approved

Earnings Report

External Links:

On September 8, 2025, Beyond Air, Inc. announced that its subsidiary NeuroNOS Limited received Orphan Drug Designation from the FDA for its therapy BA-101 targeting Glioblastoma.

AI Assistant

BEYOND AIR INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.